RS58010B1 - Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu - Google Patents

Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu

Info

Publication number
RS58010B1
RS58010B1 RS20181365A RSP20181365A RS58010B1 RS 58010 B1 RS58010 B1 RS 58010B1 RS 20181365 A RS20181365 A RS 20181365A RS P20181365 A RSP20181365 A RS P20181365A RS 58010 B1 RS58010 B1 RS 58010B1
Authority
RS
Serbia
Prior art keywords
obesity
compounds
treatment
methods
Prior art date
Application number
RS20181365A
Other languages
English (en)
Inventor
Umut Ozcan
Joseph Majzoub
Ralph Mazitschek
Isin Cakir
Serkan Cabi
Original Assignee
Childrens Medical Ct Corp
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58010(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Medical Ct Corp, Massachusetts Gen Hospital filed Critical Childrens Medical Ct Corp
Publication of RS58010B1 publication Critical patent/RS58010B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RS20181365A 2012-09-27 2013-09-26 Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu RS58010B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
EP13773562.7A EP2900230B1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof
PCT/US2013/061911 WO2014052583A1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
RS58010B1 true RS58010B1 (sr) 2019-02-28

Family

ID=49304418

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181365A RS58010B1 (sr) 2012-09-27 2013-09-26 Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu

Country Status (21)

Country Link
US (5) US9968575B2 (sr)
EP (3) EP3434268B1 (sr)
JP (2) JP6480864B2 (sr)
CN (3) CN111529534A (sr)
AU (3) AU2013323528B2 (sr)
BR (1) BR112015006848A2 (sr)
CA (2) CA2886393C (sr)
CY (1) CY1121166T1 (sr)
DK (1) DK2900230T3 (sr)
ES (1) ES2696626T3 (sr)
HK (1) HK1213190A1 (sr)
HR (1) HRP20181879T1 (sr)
HU (1) HUE040496T2 (sr)
LT (1) LT2900230T (sr)
PL (1) PL2900230T3 (sr)
PT (1) PT2900230T (sr)
RS (1) RS58010B1 (sr)
RU (2) RU2768868C2 (sr)
SI (1) SI2900230T1 (sr)
TR (1) TR201815668T4 (sr)
WO (1) WO2014052583A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434268B1 (en) 2012-09-27 2022-04-20 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
BR112016021985B1 (pt) * 2014-03-26 2022-08-30 The General Hospital Corporation Formulação farmacêutica
WO2015153933A1 (en) * 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
CA3002924A1 (en) * 2015-10-23 2017-04-27 Erx Pharmaceuticals Inc. Analogs of celastrol
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU531759B2 (en) 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
CA2223433C (en) 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
EP0836479A2 (en) 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes
AU6688896A (en) 1995-08-17 1997-03-12 Amgen, Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
EP0866720B1 (en) 1995-11-22 2004-02-11 Amgen Inc., Ob protein for increasing lean tissue mass
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法
WO1998012224A1 (en) 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
EA004790B1 (ru) 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
EP0986397A1 (en) 1997-06-06 2000-03-22 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabet
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ATE280588T1 (de) 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PT1151102E (pt) 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
DK1444516T3 (da) 2001-10-22 2010-11-15 Amgen Inc Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling
KR20050071605A (ko) * 2002-10-21 2005-07-07 메타프로테오믹스, 엘엘씨 염증반응과 관련된 병리학적 상태를 치료하거나 저해하는조성물
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
US7776484B2 (en) 2004-01-16 2010-08-17 Mitsubishi Materials Corporation Separator for fuel cell, method for producing separator, and solid oxide fuel cell
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
KR100941016B1 (ko) 2005-09-30 2010-02-05 모리나가 뉴교 가부시키가이샤 인슐린 저항성 개선제
WO2007053725A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
CA2681639A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
US20110263693A1 (en) * 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008020622A1 (fr) * 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOUVEAU COMPOSÉ DE THIÉNO[2,3-d]PYRIMIDINE
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CA2705708A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
AU2009332930A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
WO2010119674A1 (ja) * 2009-04-17 2010-10-21 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
WO2011130302A2 (en) 2010-04-12 2011-10-20 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
JP2013536203A (ja) 2010-08-23 2013-09-19 スーチョウ・ニューファーマ・カンパニー・リミテッド 特定の化学成分、組成物および方法
US20130184272A1 (en) * 2010-09-17 2013-07-18 Takeda Pharmaceutical Company Limited Diabetes therapeutic agent
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
SG11201407775WA (en) 2012-05-25 2014-12-30 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
EP3434268B1 (en) * 2012-09-27 2022-04-20 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
AU2013323528B2 (en) 2016-11-10
EP3434268A1 (en) 2019-01-30
US20170304245A1 (en) 2017-10-26
RU2650646C2 (ru) 2018-04-16
CN111529534A (zh) 2020-08-14
RU2768868C2 (ru) 2022-03-25
BR112015006848A2 (pt) 2018-05-22
CA3030272A1 (en) 2014-04-03
US10653654B2 (en) 2020-05-19
CA2886393A1 (en) 2014-04-03
DK2900230T3 (en) 2018-11-12
CY1121166T1 (el) 2020-05-29
HUE040496T2 (hu) 2019-03-28
CN104822374A (zh) 2015-08-05
EP3434268B1 (en) 2022-04-20
CA3030272C (en) 2021-09-28
HRP20181879T1 (hr) 2019-02-08
WO2014052583A1 (en) 2014-04-03
CN111529535A (zh) 2020-08-14
RU2018112067A (ru) 2019-03-07
US9925161B2 (en) 2018-03-27
PL2900230T3 (pl) 2019-02-28
EP2900230B1 (en) 2018-08-15
LT2900230T (lt) 2019-01-10
JP2019070052A (ja) 2019-05-09
US20210008019A1 (en) 2021-01-14
US20150250753A1 (en) 2015-09-10
US20210275482A1 (en) 2021-09-09
CA2886393C (en) 2019-02-26
AU2016247206A1 (en) 2016-11-10
US11045439B2 (en) 2021-06-29
AU2018256619B2 (en) 2020-07-23
RU2018112067A3 (sr) 2021-06-24
JP6743211B2 (ja) 2020-08-19
RU2015115696A (ru) 2016-11-20
AU2016247206B2 (en) 2018-08-02
ES2696626T3 (es) 2019-01-17
PT2900230T (pt) 2018-11-26
SI2900230T1 (sl) 2019-01-31
EP2900230A1 (en) 2015-08-05
JP2015531376A (ja) 2015-11-02
US20180185314A1 (en) 2018-07-05
TR201815668T4 (tr) 2018-11-21
EP4082541A1 (en) 2022-11-02
HK1213190A1 (zh) 2016-06-30
AU2018256619A1 (en) 2018-11-22
JP6480864B2 (ja) 2019-03-13
AU2013323528A1 (en) 2015-04-09
US9968575B2 (en) 2018-05-15

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for tissue treatment
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
HK1200348A1 (en) Methods and materials for treatment of pompes disease
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
ZA201408055B (en) Compositions and methods for the treatment of local pain
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408065B (en) Compositions and methods for the treatment of diabetes
EP3603631C0 (en) METHODS AND COMPOSITIONS FOR TREATING DIVERTICULOSIS
SI2819655T1 (sl) Modafinil za uporabo pri zdravljenju kokainistov
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-